La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Salarius Pharmaceuticals a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Salarius Pharmaceuticals..

Salarius Pharmaceuticals (NASDAQ:SLRX) Azioni, Catena delle Opzioni

Salarius Pharmaceuticals

Salarius Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing effective treatments for cancers with high, unmet medical needs. The company has focused on two classes of drugs that address gene dysregulation: targeted protein inhibitors and targeted protein degradation. Its Pipeline includes seclidemstat (SP-2577), a small molecular inhibitor, and SP-3164, a small molecular protein degrader.

Salarius Pharmaceuticals, Inc. - Common Stock

Salarius Pharmaceuticals Inc

Press Releases

Salarius Pharmaceuticals Announces Patient Enrollment to Resume in Investigator-initiated Phase 1/2 Clinical Trial Using Seclidemstat with Azacitidine to Treat Hematologic Cancers

Earnings

News

Salarius Pharmaceuticals Reports 2024 Financial Results and Provides Business Update

Salarius Pharmaceuticals Merger Partner, Decoy Therapeutics, Announces its Novel Inhibitors Show Promising In Silico Activity Against Measles and Related Viruses

Salarius Pharmaceuticals Merger Partner, Decoy Therapeutics, Appoints Renowned MIT Professor Robert S. Langer to its Scientific Advisory Board

Power Metallic (TSX.V: PNPN) Secures Largest Saudi License Amid June 2025 Gold Surge – Material Gains & More Stocks Inside

General

Salarius Pharmaceuticals' Seclidemstat Demonstrates Supporting Role in Inhibiting Validated Oncology Target LSD1 in Two Recently Published Studies

Salarius Pharmaceuticals Granted Additional Extension to Regain Compliance with Nasdaq's Stockholders' Equity Standard

Specificity Inc. (OTCID: SPTY) AI-Powered Technology Poised to Disrupt the Media Sector – More Stocks Inside

Salarius Pharmaceuticals Announces 1-for-15 Reverse Stock Split

Markets

Salarius Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement

ACXP

CLDI

CSE:ELEM

CSE:ESAU

DRRX

ELMGF

ESAUF

FUBO

HCTI

PNPNF

PRSO

SLRX

SNYR

TSXV:PNPN

VERV

Apollomics

Aptevo Therapeutics

AquaBounty Technologies, Inc. - Common Stock

AquaBounty Techs

Azitra

Bone Biologics

BriaCell Therapeutics

Biodexa Pharmaceuticals plc - American Depositary Shares

Biodexa Pharmaceuticals

Celularity

Dermata Therapeutics, Inc. - Common Stock

Dermata Therapeutics

ETHZilla

Galecto

GRI Bio

GT Biopharma

Indaptus Therapeutics, Inc. - Common Stock

Indaptus Therapeutics

Medicus Pharma

Psyence Biomedical Ltd. - Ordinary Shares

Psyence Biomedical

Qualigen Therapeutics, Inc. - Common Stock

Qualigen Therapeutics

Revelation Biosciences, Inc. - Common Stock

Revelation Biosciences

Revolution Medicines

Sunshine Biopharma

Scinai Immunotherapeutics Ltd. - American Depositary Shares

Scinai Immunotherapeutics

Shuttle Pharmaceuticals Holdings, Inc. - common stock

Shuttle Pharmaceuticals

Silexion Therapeutics Corp - Ordinary Shares

Silexion Therapeutics

Alaunos Therapeutics, Inc. - Common Stock

Alaunos Therapeutics

Theriva Biologics

Comments

Salarius Pharmaceuticals

Salarius Pharmaceuticals (SLRX) Opzioni

No option chain data available. Please try again later

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO